Co-Diagnostics Reports Increased Product Revenue but Faces Significant Losses in Q1 2026

Co-Diagnostics, Inc. reported a significant increase in product revenue for the first quarter of 2026, generating $145,954 compared to $50,277 in the same period of 2025. However, the company also faced a gross loss of $47,814, contrasting with a gross profit of $28,687 in the prior year. Total operating expenses rose to $9,160,597 from $8,580,643, leading to a loss from operations of $9,208,411, compared to a loss of $8,551,956 in the previous year. The net loss for the quarter was $9,140,038, or $(4.06) per share, compared to a net loss of $7,533,271, or $(7.05) per share, in the first quarter of 2025.

The company's financial position showed a decline in total assets, which decreased to $21,499,726 as of March 31, 2026, from $24,742,585 at the end of 2025. Current assets also fell significantly, from $13,693,465 to $9,782,251, primarily due to reductions in cash and cash equivalents, accounts receivable, and inventory. Current liabilities increased to $4,284,600 from $3,539,620, contributing to a rise in total liabilities to $5,457,316, up from $4,113,921. Stockholders' equity decreased to $16,042,410 from $20,628,664, reflecting the impact of the net loss.

In terms of strategic developments, Co-Diagnostics has been active in its capital-raising efforts, successfully issuing common stock through an at-the-market offering, which generated approximately $4,334,670 in net proceeds during the quarter. The company has also made organizational changes, including the adoption of a new equity incentive plan, which allows for the issuance of additional stock-based awards. As of March 31, 2026, the company had 3,764,088 shares of common stock issued, an increase from 2,256,654 shares at the end of 2025.

Operationally, the company reported a notable increase in customer engagement, with product revenue from the United States rising to $81,054 from $40,177, and revenue from the rest of the world increasing to $64,900 from $10,100. This indicates a growing market presence, with the U.S. contributing 56% of total revenue compared to 80% in the previous year, while the rest of the world accounted for 44%, up from 20%. The company’s employee headcount and operational metrics were not detailed in the filing, but the increase in product revenue suggests a potential uptick in customer adoption and engagement.

Looking ahead, Co-Diagnostics has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for additional financing to meet its operational obligations. The company plans to pursue equity and debt financing, as well as operational efficiencies, to address its capital requirements. Management has indicated that the future performance will depend on the successful execution of its business strategies and the ability to generate profitable operations.